AUNP‐12 has been proven to perform well on the antagonism of PD‐1 by subcutaneous administration and showed a safe toxicological profile.[77] Although peptide antagonists have better tumor penetration properties, short‐term retention in tumor tissues limits their application. Here, PDCD1 is linked to neoplasm.